Summary The low-affinity monoclonal antibody (MAb) chimeric 17-lA(c-17-lA) and the high-affinity MAb mouse 323/A3 (m-323/A3) were used to study the effect of the MAb affinity on the tumour uptake and efficacy of radioimmunotherapy in nude mice bearing subcutaneously the human ovarian cancer xenografts FMa, OVCAR-3 and Ov.Pe. Both MAbs are directed against the same pancarcinoma glycoprotein. In vitro, the number of binding sites on tumour cells at 40C was similar for both MAbs, but m-323/A3 had an approximately 5-fold higher affinity (1.3 -3.0 x 109M-') than c-17-lA (3.0 -.4 x IO' M-). This difference in affinity was more extreme at 37°C, when no binding of c-17-IA could be observed. MAb m-323/A3 completely blocked the binding of c-17-lA to tumour cells, whereas the reverse was not observed. Immunohistochemistry showed a similar but more intense staining pattern of m-323/A3 in human ovarian cancer xenografts than of c-17-1A. In vivo, the blood clearance in non-tumour-bearing nude mice was similar for both MAbs with terminal half-lives of 71.4 h for m-323/A3 and 62.7 h for c-17-lA. MAb m-323/A3 targeted better to tumour tissue, but was more heterogeneously distributed than c-17-lA. The cumulative absorbed radiation dose delivered by m-323/A3 to tumour tissue was 2.5-to 4.7-fold higher than that delivered by c-17-lA. When mice were treated with equivalent radiation doses of ['311]m-323/A3 and ['31I]c-17-lA, based on a correction for the immunoreactivity of the radiolabelled MAbs, m-323/A3 induced a better growth inhibition in two of the three xenografts. When the radiation doses were adjusted to obtain a similar amount of radiation in the tumour c-17-lA was more effective in tumour growth inhibition in all three xenografts.
The uptake of monoclonal antibodies (MAbs) in tumour tissue is influenced by a number of factors, including the MAb affinity. Whether low-or high-affinity MAbs should be used in tumour diagnosis or therapy is under current investigation. Theoretically, a MAb with a high affinity has a higher percentage of uptake and an increased retention time in the tumour, although the penetration is limited. As a result of its efficient binding to the antigen near blood vessels, a lower percentage of free MAb is available to percolate into the tumour. Experimental evidence for the presence of a binding-site barrier for high-affinity MAbs has been demonstrated by the group of Weinstein (Juweid et al., 1992) . In contrast, MAbs with a low affinity penetrate deeper into the tumour but show a lower tumour uptake and have a shorter retention time.
The human antigen encoded by the GA 733-2 gene is a 38-40 kDa transmembrane glycoprotein expressed on the basolateral surface of normal epithelial cells in secretory tissues (Linnenbach et al., 1993; Momburg et al., 1987) . The antigen is highly expressed in adenocarcinomas, including those from the colon, breast, ovary and lung (Momburg et al., 1987) . Therefore, the antigen may be a good target for immunoscintigraphy and immunotherapy. MAb mouse 17-lA (Koprowski et al., 1979) , the first MAb generated against this antigen, has been successfully used for radioimmunolocalisation of colorectal cancer lesions in patients (Chatal et al., 1984) . The uptake of i.v.-administered 17-lA in normal tissues was low, indicating that the basal membrane, which is absent or disrupted in tumours, prevents 17-lA from reaching the antigen on normal epithelial cells. As 17-lA is also able to induce antibody-dependent cellular cytotoxicity (ADCC), colorectal cancer patients have been treated with unconjugated mouse 17-lA and sporadic responses were observed (Mellstedt et al., 1991) . A reduced recurrence rate and an increased survival time have been observed in patients with operable colorectal cancer receiving unconjugated mouse 17-lA as adjuvant therapy (Riethmiiller et al., 1994) . In the further development of MAb 17-lA for treatment humanmouse chimeric forms of 17-lA have been produced in order to reduce the human anti-mouse immunoglobulin (HAMA) response. Chimeric 17-lA IgGI was found to be equally effective in tumour uptake and in efficacy in radioimmunotherapy of tumour-bearing nude mice when compared with mouse 17-lA (Buchsbaum et al., 1990) . In addition, chimeric 17-lA IgGI showed a prolonged circulation time and a reduced immunogenicity in patients (Meredith et al., 1991) . These data indicate that chimeric 17-lA IgGI may have advantages for the diagnosis and therapy of cancer.
Another MAb directed against the 17-lA antigen is mouse 323/A3 (Edwards et al., 1986) , which recognises an identical or overlapping epitope but has a higher affinity when compared with 17-lA (Pak et al., 1991) . Although 323/A3 was primarily developed for the diagnosis of breast cancer, other adenocarcinomas of the colon, ovary, pancreas and lung showed positive staining with 323/A3 as well (Pak et al., 1991) . In addition, mouse 323/A3 rapidly localised into human colorectal cancer and breast cancer xenografts in nude mice (Pak et al., 1991) . This high-affinity MAb may therefore be a good candidate for clinical evaluation.
In this study we compared the MAbs chimeric 17-lA (c-17-lA) and mouse 323/A3 (m-323/A3) to investigate the influence of the MAb affinity on tumour uptake and efficacy of radioimmunotherapy. Both MAbs were analysed in vitro for their binding characteristics with human ovarian cancer and colon cancer cells. In vivo, the pharmacokinetics of c-17-IA and m-323/A3 was determined in non-tumour-bearing mice, whereas their tumour-targeting properties and efficacy in radioimmunotherapy were studied in mice bearing human ovarian cancer xenografts. Tumours, blood and normal organs (heart, lung, sternum, liver, spleen, stomach, ileum, colon, kidney, bladder, muscle, skin, fat) were collected, weighed and counted in a gamma counter. The % ID g-1 tissue, corrected for the physical decay of the radionuclides, was then calculated and plotted vs time. From the area under the curve (AUC), the absorbed cumulative radiation doses were calculated using the trapezoid integration method. These doses were expressed in cGy by multiplying the integrated ,uCi h g-1 by the g cGy uCi-h-1 factor for 131I (0.3985: Dillman, 1969) , assuming a similar distribution pattern for 1251-and "3'I-labelled MAbs. 10 MCi of m-323/A3, c-17-lA, m-E48 and c-anti-CD4 in blood, tumour, liver, spleen and kidney were calculated from the data of the biodistribution experiments (Table II) . The absorbed doses in blood exceeded those in the tumours, except for m-323/A3 in mice bearing FMa xenografts. The radiation dose delivered by m-323/A3 to FMa, OVCAR-3 and Ov.Pe xenografts was 4.7-, 2.6-and 2.5-fold, respectively, higher than that delivered by c-17-lA. The liver, spleen and kidney received similar low doses of m-323/A3 and c-17-lA, which were similar to those delivered by m-E48 and c-anti-CD4.
The xenografts, whereas c-17-IA showed a more homogeneous pattern (Figure 3 ). This phenomenon was observed 24 h after injection and did not change noticeably in the following 3 days. The radioactivity density profiles illustrate the differences in uptake and in distribution between both MAbs. Owing to the lower uptake of m-323/A3 and c-17-IA in OVCAR-3 xenografts, it was more difficult to observe a difference in the distribution between the antibodies, but again m-323/A3 was heterogeneously distributed throughout the tumour (Figure 4 ).
Radioimmunotherapy
In previously performed maximum tolerated dose (MTD) ['3 'I]c-17-lA. These half-lives were independent of the doses administered. The whole-body absorbed radiation doses were in agreement with the radiation dose administered.
As both m-323/A3 and c-17-IA are able to induce ADCC, the therapeutic effect of unlabelled m-323/A3 and c-17-lA was studied in FMa-bearing mice using the same injection schedule as in the radioimmunotherapy experiments. When mice were treated with m-323/A3 or c-17-lA at protein doses exceeding those used in the radioimmunotherapy experiments (200 ,ug) , 1992) . At 37°C we observed no binding of c-17-lA, whereas the binding of m-323/A3 was not affected. Lower binding of 17-1A with increasing temperature has been reported before (Oredipe et al., 1992; Langmuir et al., 1992) . Changes in membrane fluidity at 37°C resulting in a physical barrier for 17-lA to bind to its epitope could be the cause of the reduced binding of 17-lA, as was suggested by the group of Langmuir. In vivo, however, we could still demonstrate specific uptake of c-17-lA in human ovarian cancer xenografts.
Competition assays at 4°C showed a complete inhibition of the binding of c-17-IA to tumour cells by m-323/A3, whereas m-323/A3 was still able to bind to tumour cells that were preincubated with c-17-1A. This phenomenon has been reported before (Pak et al., 1991; Langmuir et al., 1992) MAb m-323/A3 targeted better to tumour tissue than c-17-1A. The cumulative absorbed radiation doses in FMa, OVCAR-3 and Ov.Pe xenografts delivered by m-323/A3 were higher than those delivered by c-17-lA, even when corrections were made for the immunoreactive fractions of the MAbs after radiolabelling. Also, m-323/A3 remained longer in tumour tissue than c-17-lA. These results can most likely be explained by the extreme difference in affinity between both MAbs at 37°C. However, other factors such as differences in the quantity and accessibility of the epitopes could have an effect on the tumour uptake as well. Autoradiography showed a heterogeneous distribution pattern of a low protein dose of m-323/A3 in tumour tissue, whereas c-17-1A was more homogeneously distributed.
These findings are in agreement with the hypothesis of a perivascular binding for high-affinity MAbs and a deeper penetration for low-affinity MAbs in tumour tissue (Juweid et al., 1992) .
Although m-323/A3 showed a similar strong reactivity pattern with frozen sections of all three human ovarian cancer xenografts in vitro, the tumour uptake of m-323/A3 in vivo varied between the xenografts. Blumenthal et al. (1992a) have also found a variation in uptake of a radiolabelled anti-CEA MAb in different human colon cancer xenografts, which was most likely due to differences in the intratumoral and intracellular distribution of CEA. We found m-323/A3 staining of the membrane and the cytoplasm of tumour cells throughout the whole xenograft tissue sections, indicating a homogeneous distribution of the antigen. To obtain more insight into the differences in the uptake of m-323/A3 in these xenografts, we are currently analysing other factors of influence, including tumour perfusion, tumour vascularisation pattern and the antigen content.
In (Jurcic and Scheinberg, 1994) . The effect of MAb affinity on the efficacy of radioimmunotherapy has been studied before, but the preference for low-or high-affinity MAbs was still elusive. In vivo, better tumour-targeting properties have been reported for a high affinity anti-CEA MAb (Hansen et al., 1993) , but the MAb was equally effective in radioimmunotherapy when compared with a similar radiation dose of a low-affinity anti-CEA MAb (Blumenthal et al., 1992b) . In this study no corrections were made for the immunoreactivity of the MAbs after radiolabelling. Other in vivo studies have reported an improved localisation as well as a therapeutic advantage for radiolabelled high-affinity MAbs against the TAG-72 antigen when compared with a low affinity anti-TAG-27 MAb (Colcher et al., 1988; Schlom et al., 1992) . Even with a 2.5-to 3-fold lower radiation dose of the high-affinity MAbs, which might compensate for the lower amount of absorbed radiation dose delivered by the low-affinity MAb, better antitumour effects were observed for the high-affinity MAbs. This is in contrast with the present experiments, in which we clearly show that the low-affinity MAb c-17-lA is superior to the high-affinity MAb m-323/A3 in tumour growth inhibition when similar amounts of radiation are delivered to the tumour. Nevertheless, 323/A3, preferably in the chimeric form, may be favourable for use in radioimmunotherapy as higher radiation doses of c-17-lA required to obtain similar or better anti-tumour effects will be associated with increased side-effects. In addition, m-323/A3 targets better to tumour tissue and may therefore be more efficient in immunoscintigraphy of tumour lesions in patients.
